United Therapeutics Corporation (Nasdaq:UTHR) hit a new 52-week high Wednesday as it is currently trading at $63.12, above its previous 52-week high of $63.11 with 749,976 shares traded as of 2:36 p.m. ET. Average volume has been 768,800 shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- United Therapeutics Corporation (Nasdaq: UTHR) hit a new 52-week high Wednesday as it is currently trading at $63.12, above its previous 52-week high of $63.11 with 749,976 shares traded as of 2:36 p.m. ET. Average volume has been 768,800 shares over the past 30 days. United has a market cap of $3.07 billion and is part of the health care sector and drugs industry. Shares are up 14.5% year to date as of the close of trading on Tuesday. United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. The company has a P/E ratio of 10.7, below the S&P 500 P/E ratio of 17.7.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates United as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full United Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.